Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

  • Name

    Takeda Pharmaceutical Company Limited

  • CEO

    Mr. Christophe Weber

  • Website

    www.takeda.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1781

Profile

  • Market Cap

    ¥6,702.37B

  • EV

    ¥12T

  • Shares Out

    1,584.86M

  • Revenue

    ¥4,413.13B

  • Employees

    49,281

Margins

  • Gross

    66.07%

  • EBITDA

    26.61%

  • Operating

    11.54%

  • Pre-Tax

    1.23%

  • Net

    3.4%

  • FCF

    13.76%

Returns (5Yr Avg)

  • ROA

    1.69%

  • ROTA

    17.3%

  • ROE

    4.06%

  • ROCE

    4.43%

  • ROIC

    -7.87%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    ¥4,768.83

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    ¥804.27B

  • Net Debt

    ¥5,293.1B

  • Debt/Equity

    0.78

  • EBIT/Interest

    4.41

Growth (CAGR)

  • Rev 3Yr

    9.67%

  • Rev 5Yr

    12.07%

  • Rev 10Yr

    10.06%

  • Dil EPS 3Yr

    -29.84%

  • Dil EPS 5Yr

    11.39%

  • Dil EPS 10Yr

    -3.27%

  • Rev Fwd 2Yr

    2.3%

  • EBITDA Fwd 2Yr

    13.84%

  • EPS Fwd 2Yr

    28.18%

  • EPS LT Growth Est

    12.41%

Dividends

  • Yield

  • Payout

    196.64%

  • DPS

    ¥188

  • DPS Growth 3Yr

    1.46%

  • DPS Growth 5Yr

    0.87%

  • DPS Growth 10Yr

    0.44%

  • DPS Growth Fwd 2Yr

    3.37%

TSE:4502